[시장보고서]세계의 단백질체학 시장 : 계장별, 시약별, 서비스별, 소프트웨어별, 용도별 예측(-2029년)

세계의 단백질체학 시장 : 계장별, 시약별, 서비스별, 소프트웨어별, 용도별 예측(-2029년)

Proteomics Market by Instrumentation (Mass Spectrometry, HPLC, Electrophoresis, Protein Microarray (Protein Chips)), Reagents, Services (Purification, Bioinformatics), Software, Application (Clinical, Drug Discovery) - Global Forecast to 2029

상품코드 : 1563532 해당 상품은 즉시 배송 가능합니다

리서치사 : MarketsandMarkets

발행일 : 2024년 09월

페이지 정보 : 영문 798 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,950

￦ 7,146,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,650

￦ 9,601,000

PDF (5-user License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,150

￦ 11,766,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 이용 인원에 제한은 없으나, 국내에 있는 사업장만 해당되며, 해외 지점 등은 포함되지 않습니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000

￦ 14,438,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. (100% 자회사는 동일 기업으로 간주됩니다.) 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

세계의 단백질체학 시장 규모는 2024년 336억 달러에서 2029년까지 605억 달러에 이를 것으로 추정되며, 예측 기간 동안 복합 연간 성장률(CAGR) 12.4%의 성장이 예상됩니다.

조사 범위
조사 대상년도	2021년-2029년
기준년	2023년
예측 기간	2024년-2029년
단위	10억 달러
부문	계측, 시약, 서비스, 소프트웨어, 용도, 최종 사용자
대상 지역	북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카

"분광법 부문이 시장에서 압도적인 점유율을 차지합니다."

분광법은 단백질의 구조, 크기, 모양, 2차 또는 3차 구조, 정량화, 리간드, 용질 및 기타 단백질과 같은 다른 분자와의 상호작용에 대한 정보를 제공하며, 단백질 분석에서의 사용이 증가합니다. 같은 요인으로 인해 48.8%의 최대 점유율을 차지했습니다.

"이뮤노 분석 시약이 시약 부문을 독점했습니다."

시약 부문에서 면역 측정 시약은 26.5%의 가장 큰 점유율을 차지했지만, 분광 시약은 예측 기간 동안 상당한 복합 연간 성장률(CAGR)로 성장할 것으로 예상됩니다. 질 수량 분석 기반 접근법의 사용 증가, 높은 처리량 질 수량 분석 접근법의 개발, 개인화된 의료에 대한 관심 증가 등의 요인이 이 부문의 성장을 가속할 가능성이 높습니다.

"바이오 의약품 기업 부문은 예측 기간에 높은 복합 연간 성장률(CAGR)로 성장할 가능성이 높습니다."

바이오의약품 기업 부문은 신분자의 발견과 개발, 바이오마커의 동정, 맞춤형 의료를 위한 연구개발 증가 등 핵심 활동에 대기업 제약기업이 주력하게 됨으로써 단백질체학 시장에서 39.1%의 최대 점유율을 차지했습니다.

"아시아태평양이 가장 높은 성장률을 보일 것으로 추정됩니다."

2023년 북미는 단백질체학 시장의 큰 점유율을 차지했습니다. 아시아태평양은 단백질체학와 유전체학 연구 분야의 확대와 연구조사를 위한 자금조달 증가 등 다양한 요인으로 인해 예측기간에 높은 복합 연간 성장률(CAGR)로 성장할 가능성이 높습니다. 바이오 의약품 기업에 의한 투자 증가, mAb 기반 치료 분야에서의 연구 활동의 활성화가 이 지역 시장 확대를 촉진할 것으로 보입니다.

본 보고서는 세계의 단백질체학 시장에 대한 조사 분석을 통해 주요 촉진요인과 억제요인, 경쟁 구도, 미래 동향 등의 정보를 제공합니다.

소개
시장 역학
- 성장 촉진요인
- 억제요인
- 기회
- 과제
고객의 비즈니스에 영향을 미치는 동향/혼란
기술 분석
- 주요 기술
- 보완 기술
- 인접 기술
가격 분석
- 단백질체학 기구 시장의 판매 가격의 동향 :지역별(2021년-2023년)
- 단백질체학 기구의 평균 판매 가격의 동향 :지역별(2023년)
밸류체인 분석
공급망 분석
생태계 분석
- 단백질체학 제품/서비스 제공업체
- 최종 사용자
- 규제기관
특허 분석
무역 분석
- 크로마토그래피,전기 영동 기구의 수입 데이터(HS 코드:902720)
- 크로마토그래피,전기 영동 기구의 수출 데이터(HS 코드:902720)
- 질수량 분석계의 수입 데이터(HS 코드:902781)
- 질수량 분석계의 수출 데이터(HS 코드:902781)
주요 컨퍼런스 및 이벤트(2024년-2025년)
규제 상황
- 규제 시나리오
- 규제기관, 정부기관, 기타 조직
투자와 자금조달 시나리오
Porter's Five Forces 분석
주요 이해관계자와 구매 기준
단백질체학 시장에 대한 AI/생성형 AI의 영향

제6장 단백질체학 시장 : 계장 기술별

소개
분광법
- 질 수량 분석
- NMR 분광법
- CD 분광법
크로마토그래피
- 고속 액체 크로마토그래피
- 이온 크로마토그래피
- 친화성 크로마토그래피
- 초임계 유체 크로마토그래피
전기영동
- 겔 전기영동
- 모세관 전기 영동
단백질 마이크로어레이
- 바이오칩
- 마이크로어레이 기구
X선 결정 구조 해석
표면 플라즈몬 공명
단백질 분획
기타 계장 기술

제7장 단백질체학 시장 : 시약별

소개
면역 측정 시약
분광법 시약
크로마토그래피 시약
단백질 마이크로어레이 시약
X선 결정 구조 해석 시약
전기영동 시약
단백질 분획 시약
기타 시약

제8장 단백질체학 시장 : 서비스별

소개
코어 단백질체학 서비스
- 단백질 식별 서비스
- 정량적 단백질체학 서비스
- 단백질 특성 평가 서비스
- 단백질 정제 서비스
- 단백질 분리 서비스
- 단백질 서열 분석 서비스
- 맞춤형 분석 서비스
바이오인포매틱스 서비스

제9장 단백질체학 시장 : 소프트웨어별

소개
- 바이오인포매틱스 툴
- 바이오인포매틱스 데이터베이스

제10장 단백질체학 시장 : 용도별

소개
임상 진단
- 암
- 감염증
- 당뇨병
- 신경질환
- 자가면역질환
- 심혈관 질환
- 기타 임상 진단 용도
창약?의약품 개발
- 표적의 발견
- 리드 특정
- 리드 최적화
- 전임상 연구
기타 용도

제11장 단백질체학 시장 : 최종 사용자별

소개
바이오의약품기업
학술연구기관
병원
임상 실험실
기타 최종 사용자

제12장 단백질체학 시장 : 지역별

소개
북미
- 북미의 거시경제 전망
- 미국
- 캐나다
유럽
- 유럽의 거시 경제 전망
- 독일
- 영국
- 프랑스
- 스위스
- 이탈리아
- 스페인
- 기타 유럽
아시아태평양
- 아시아태평양의 거시 경제 전망
- 중국
- 일본
- 인도
- 한국
- 호주
- 기타 아시아태평양
라틴아메리카
- 라틴아메리카의 거시 경제 전망
- 브라질
- 멕시코
- 기타 라틴아메리카
중동
- 중동의 거시 경제 전망
- GCC 국가
- 기타 중동
아프리카

제13장 경쟁 구도

소개
주요 기업의 전략/유력 기업
수익 분석(2021년-2023년)
시장 점유율 분석(2023년)
기업의 평가 매트릭스: 주요 기업(2023년)
기업의 평가 매트릭스: 스타트업/중소기업(2023년)
기업 평가 및 재무 지표
브랜드/제품 비교
경쟁 시나리오

제14장 기업 프로파일

주요 기업
- THERMO FISHER SCIENTIFIC INC.
- AGILENT TECHNOLOGIES, INC.
- MERCK KGAA
- DANAHER CORPORATION
- SHIMADZU CORPORATION
- WATERS CORPORATION
- BIO-RAD LABORATORIES, INC.
- BRUKER
- REVVITY
- ILLUMINA, INC.
- PROMEGA CORPORATION
- EUROFINS SCIENTIFIC
- QIAGEN
- CHARLES RIVER LABORATORIES
- PROTAGENE
기타 기업
- CREATIVE PROTEOMICS, US
- HORIBA JAPAN LTD.
- SENGENICS CORPORATION LLC
- LABVANTAGE-BIOMAX GMBH
- FIOS GENOMICS
- AZENTA US, INC.
- MEDGENOME
- BIOGNOSYS AG
- MACROGEN, INC.
- CELL SIGNALING TECHNOLOGY, INC.

제15장 부록

BJH

영문 목차

영문목차

The global proteomics market is estimated to reach USD 60.5 billion by 2029 from USD 33.6 billion in 2024, at a CAGR of 12.4% during the forecast period of 2024 to 2029.

Scope of the Report
Years Considered for the Study	2021-2029
Base Year	2023
Forecast Period	2024-2029
Units Considered	Value (USD Billion)
Segments	Instrumentation, Reagents, Services, Software, Application and End User
Regions covered	North America, Europe, Asia Pacific, Latin America, Middle East & Africa

"The spectroscopy segment holds dominant share in the proteomics market."

Based on the technology, the proteomics market is divided into spectroscopy, chromatography, electrophoresis, protein microarrays, X-ray crystallography, surface plasmon resonance, protein fractionation, and other technologies. The spectroscopy segment accounted for the largest share of 48.8% owing to factors such as technique is increased use in protein analysis, providing information about protein structure, size, shape, secondary or tertiary conformation, quantification, and interaction with other molecules, such as ligands, solutes, or other proteins.

"The immunoassay reagent dominated the reagent segments."

Based on reagent, the proteomics market is segmented into, protein microarray reagents, spectroscopy reagents, X-ray crystallography reagents, chromatography reagents, electrophoresis reagents, immunoassay reagents, and protein fractionation reagents. The immunoassay reagents accounted for the largest share of 26.5% of the reagent segment however spectroscopy reagent is anticipated to grow at significant CAGR during the forecast period. Factors like growing use of mass spectrometry-based techniques, development of high-throughput mass spectrometry techniques and increasing interest in personalized medicine are likely to drive the segmental growth.

"Biopharmaceutical companies segment is likely to grow at significant CAGR during the forecast period"

Based on end user, the proteomics market is segmented into hospitals, clinical laboratories, biopharmaceutical companies, academic & research institutes, and other end users. The biopharmaceutical companies segment accounted for the largest share of 39.1% of the proteomics market owing to rising focus of pharma giants on core activities like increasing R&D for the discovery and development of new molecules, identification of biomarkers and personalized medicine.

"Asia Pacific region estimated to show fastest growth rate."

Geographically, the proteomics market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East and Africa. In 2023, North America accounted for the major share of the proteomics market. The Asia Pacific region is likely to grow at significant CAGR during the forecast period owing to various factors such as growing fields of proteomics and genomics research in conjunction with an increase in funding toward research studies. Rising investment by biopharmaceutical companies, growing research activity in the area of mAb-based therapeutics are likely to drive market expansion in the region.

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply Side- 70%, and Demand Side - 30%
By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, Executives- 25%
By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, MEA- 5%

List of Companies Profiled in the Report:

Thermo fisher Scientific Inc (US)
Agilent Technologies, Inc. (US)
Merck KGaA (Germany)
Danaher Corporation (US)
Waters Corporation (US)
Bio-Rad Laboratories, Inc. (US)
Bruker Corporation (US)
Revvity (US)
Shimadzu Corporation (Japan)
Illumina Inc (US)
Promega Corporation (US)
Eurofins Scientific (Luxembourg)
Qiagen (Netherlands)
Charles River Laboratories (US)
Protagene (Germany)
Creative Proteomics (US)
Horiba (Japan)
Sengenics Corporation LLC (US)
Labvantage-Biomax GmbH (Germany)
Cell Signaling Technology, Inc. (US)
FIOS Genomics (UK)
Azenta Life Sciences (US)
Medgenome (India)
Biognosys AG (Switzerland)
Macrogen Inc (South Korea)

Research Coverage:

This report provides a detailed picture of the proteomics market. It aims at estimating the size and future growth potential of the market across different segments such as technology, reagent, service, software, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

Analysis of key Drivers (Growing demand for personalized medicines for clinical practices, Increased investments in proteomics research and development, Rising Application in Drug Discovery and Development and Government and Private Funding) restraints (High costs of proteomics instruments and technologies, Lack of standardization in proteomics techniques) opportunities (Advancements in Bioinformatics, Advancements in Single-Cell Proteomics and Collaborations and Partnerships) and challenges (Lack of data management/handling in proteomics research) influencing the growth of the market.
Product Development/Innovation: Detailed insights on newly launched products and technological assessment of the proteomics market.
Market Development: Comprehensive information about lucrative markets the report analyses the market across varied regions.
Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the proteomics market.
Competitive Assessment: In-depth assessment of market shares, growth strategies, and products offerings of leading players like Thermo fisher Scientific Inc (US), Agilent Technologies, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), Waters Corporation (US), Bio-Rad Laboratories, Inc. (US), Bruker Corporation (US), Revvity (US), Shimadzu Corporation (Japan), Illumina Inc (US), Promega Corporation (US), Eurofins (Luxembourg), Qiagen (Netherlands), Charles River Laboratories (US), Protagene (Germany), Creative Proteomics (US), Horiba (Japan), Sengenics Corporation LLC (US), Labvantage-Biomax GmbH (Germany), Cell Signaling Technology, Inc. (US), FIOS Genomics (UK), Azenta Life Sciences (US), Medgenome (India), Biognosys AG (Switzerland) and Macrogen Inc (South Korea).

1 INTRODUCTION

1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
- 1.3.1 SEGMENTS CONSIDERED
- 1.3.2 INCLUSIONS AND EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
- 1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

2.1 RESEARCH DATA
- 2.1.1 SECONDARY DATA
  - 2.1.1.1 Key secondary sources
  - 2.1.1.2 Objectives of secondary research
- 2.1.2 PRIMARY DATA
  - 2.1.2.1 Objectives of primary research
2.2 MARKET SIZE ESTIMATION
- 2.2.1 REVENUE SHARE ANALYSIS (BOTTOM-UP APPROACH)
- 2.2.2 MNM REPOSITORY ANALYSIS
- 2.2.3 PRIMARY INTERVIEWS
- 2.2.4 SECONDARY RESEARCH
- 2.2.5 INSIGHTS FROM PRIMARIES
- 2.2.6 TOP-DOWN APPROACH
- 2.2.7 MARKET GROWTH RATE PROJECTIONS
2.3 DATA TRIANGULATION
2.4 STUDY ASSUMPTIONS
2.5 RESEARCH LIMITATIONS
2.6 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PROTEOMICS MARKET OVERVIEW
4.2 NORTH AMERICA: PROTEOMICS MARKET, BY APPLICATION, 2023
4.3 SPECTROSCOPY INSTRUMENTATION TECHNOLOGY MARKET, BY TYPE, 2024 VS. 2029
4.4 PROTEOMICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

5.1 INTRODUCTION
5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
  - 5.2.1.1 Growing demand for personalized medicines in clinical practices
  - 5.2.1.2 High investments in pharmaceutical R&D
  - 5.2.1.3 Rising applications in drug discovery and development
  - 5.2.1.4 Increased private and government funding
- 5.2.2 RESTRAINTS
  - 5.2.2.1 High costs of proteomics instruments and technologies
  - 5.2.2.2 Lack of standardization
- 5.2.3 OPPORTUNITIES
  - 5.2.3.1 Advancements in bioinformatics
  - 5.2.3.2 Developments in single-cell proteomics research
  - 5.2.3.3 Increasing number of collaborations and strategic partnerships
- 5.2.4 CHALLENGES
  - 5.2.4.1 Lack of data management and handling
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.4 TECHNOLOGY ANALYSIS
- 5.4.1 KEY TECHNOLOGIES
  - 5.4.1.1 Mass spectrometry
    - 5.4.1.1.1 Intact or top-down protein analysis
  - 5.4.1.2 Chromatography
  - 5.4.1.3 Protein microarrays
- 5.4.2 COMPLEMENTARY TECHNOLOGIES
  - 5.4.2.1 Transcriptomics
  - 5.4.2.2 Metabolomics
- 5.4.3 ADJACENT TECHNOLOGIES
  - 5.4.3.1 Single-cell proteomics
5.5 PRICING ANALYSIS
- 5.5.1 INDICATIVE SELLING PRICE TREND FOR PROTEOMICS INSTRUMENTS MARKET, BY REGION, 2021-2023
- 5.5.2 AVERAGE SELLING PRICE TREND OF PROTEOMICS INSTRUMENTS, BY REGION, 2023
5.6 VALUE CHAIN ANALYSIS
5.7 SUPPLY CHAIN ANALYSIS
5.8 ECOSYSTEM ANALYSIS
- 5.8.1 PROTEOMICS PRODUCT AND SERVICE PROVIDERS
- 5.8.2 END USERS
- 5.8.3 REGULATORY BODIES
5.9 PATENT ANALYSIS
- 5.9.1 METHODOLOGY
- 5.9.2 NUMBER OF PATENTS APPLIED AND GRANTED, BY DOCUMENT TYPE, 2013-2024
- 5.9.3 INNOVATION AND PATENT APPLICATION
- 5.9.4 TOP TEN PLAYERS WITH HIGHEST NUMBER OF APPLICATIONS
- 5.9.5 TOP 10 PATENT OWNERS
- 5.9.6 KEY PATENTS IN PROTEOMICS MARKET
5.10 TRADE ANALYSIS
- 5.10.1 IMPORT DATA FOR CHROMATOGRAPHS AND ELECTROPHORESIS INSTRUMENTS (HS CODE: 902720)
- 5.10.2 EXPORT DATA FOR CHROMATOGRAPHS AND ELECTROPHORESIS INSTRUMENTS (HS CODE: 902720)
- 5.10.3 IMPORT DATA FOR MASS SPECTROMETERS (HS CODE: 902781)
- 5.10.4 EXPORT DATA FOR MASS SPECTROMETERS (HS CODE: 902781)
5.11 KEY CONFERENCES AND EVENTS, 2024-2025
5.12 REGULATORY LANDSCAPE
- 5.12.1 REGULATORY SCENARIO
  - 5.12.1.1 North America
  - 5.12.1.2 Europe
  - 5.12.1.3 Asia Pacific
  - 5.12.1.4 Rest of the world
- 5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.13 INVESTMENT AND FUNDING SCENARIO
5.14 PORTER'S FIVE FORCES ANALYSIS
- 5.14.1 THREAT OF NEW ENTRANTS
- 5.14.2 THREAT OF SUBSTITUTES
- 5.14.3 BARGAINING POWER OF BUYERS
- 5.14.4 BARGAINING POWER OF SUPPLIERS
- 5.14.5 INTENSITY OF COMPETITIVE RIVALRY
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
- 5.15.1 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
- 5.15.2 KEY BUYING CRITERIA
5.16 IMPACT OF AI/GEN AI ON PROTEOMICS MARKET

6 PROTEOMICS MARKET, BY INSTRUMENTATION TECHNOLOGY

6.1 INTRODUCTION
6.2 SPECTROSCOPY
- 6.2.1 MASS SPECTROMETRY
  - 6.2.1.1 High specificity and technological advancements to propel segment growth
- 6.2.2 NMR SPECTROSCOPY
  - 6.2.2.1 Accurate evaluation of physical, chemical, electronic, and structural information of proteins to aid segment growth
- 6.2.3 CD SPECTROSCOPY
  - 6.2.3.1 Non-destructive and non-invasive techniques to examine changes in secondary protein structures
6.3 CHROMATOGRAPHY
- 6.3.1 HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY
  - 6.3.1.1 High resolution, sensitivity, and reproducibility to spur segment growth
- 6.3.2 ION CHROMATOGRAPHY
  - 6.3.2.1 High resolving power, simplicity, and controllability to separate and purify proteins
- 6.3.3 AFFINITY CHROMATOGRAPHY
  - 6.3.3.1 High specificity for target proteins and easy identification of novel protein interactions to drive segment
- 6.3.4 SUPERCRITICAL FLUID CHROMATOGRAPHY
  - 6.3.4.1 Ability to separate complex protein mixtures with high efficiency and speed to fuel segment growth
6.4 ELECTROPHORESIS
- 6.4.1 GEL ELECTROPHORESIS
  - 6.4.1.1 Increasing demand for proteomics research and personalized medicine to boost segment growth
- 6.4.2 CAPILLARY ELECTROPHORESIS
  - 6.4.2.1 Low diffusion coefficients of biomolecules and easy elimination of sample carryover between measurements to drive market
6.5 PROTEIN MICROARRAYS
- 6.5.1 BIOCHIPS
  - 6.5.1.1 Lab-on-chips
    - 6.5.1.1.1 Rising focus on microfabrication and nanotechnology development to aid segment growth
  - 6.5.1.2 Protein chips
    - 6.5.1.2.1 Competitive advantage over conventional protein analysis tools to propel segment growth
- 6.5.2 MICROARRAY INSTRUMENTS
  - 6.5.2.1 Integrated systems
    - 6.5.2.1.1 Integrated systems to enable high-throughput and reproducible analysis of proteins
  - 6.5.2.2 Microarray scanners
    - 6.5.2.2.1 Cost-effective and high-quality analysis to propel segment growth
  - 6.5.2.3 Arrayers
    - 6.5.2.3.1 Technological advancements to drive adoption of arrayers in large-scale projects
6.6 X-RAY CRYSTALLOGRAPHY
- 6.6.1 RISING NEED FOR HIGH-RESOLUTION INFORMATION ON PROTEIN STRUCTURES TO AUGMENT MARKET GROWTH
6.7 SURFACE PLASMON RESONANCE
- 6.7.1 INCREASING ABILITY TO BIND AFFINITIES AND KINETICS OF COMPLEXES TO PROPEL MARKET GROWTH
6.8 PROTEIN FRACTIONATION
- 6.8.1 PROTEIN FRACTIONATION TO ENABLE EFFECTIVE SEPARATION OF PROTEINS IN COMPLEX MIXTURES
6.9 OTHER INSTRUMENTATION TECHNOLOGIES

7 PROTEOMICS MARKET, BY REAGENT

7.1 INTRODUCTION
7.2 IMMUNOASSAY REAGENTS
- 7.2.1 NEED FOR RELIABLE, SPECIFIC, AND FAST DISEASE DETECTION AT EARLY STAGES TO FAVOR MARKET GROWTH
7.3 SPECTROSCOPY REAGENTS
- 7.3.1 INCREASED ADOPTION OF HIGH-THROUGHPUT MASS SPECTROSCOPY-BASED TECHNIQUES TO AID MARKET GROWTH
7.4 CHROMATOGRAPHY REAGENTS
- 7.4.1 BETTER ACCURACY AND LOWER DETECTION LIMITS TO FACILITATE SEGMENT GROWTH
7.5 PROTEIN MICROARRAY REAGENTS
- 7.5.1 DEVELOPMENT OF NOVEL AND ADVANCED PROTEIN ANALYSIS REAGENTS TO PROPEL MARKET GROWTH
7.6 X-RAY CRYSTALLOGRAPHY REAGENTS
- 7.6.1 EMERGENCE OF NEW TARGETS FOR DRUG DISCOVERY AND HIGH R&D INVESTMENTS TO SUPPORT MARKET GROWTH
7.7 ELECTROPHORESIS REAGENTS
- 7.7.1 INCREASING DEMAND FOR 2D ELECTROPHORESIS TO AUGMENT MARKET GROWTH
7.8 PROTEIN FRACTIONATION REAGENTS
- 7.8.1 RISING NEED FOR PROTEIN FRACTIONATION TECHNIQUES TO AUGMENT MARKET GROWTH
7.9 OTHER REAGENTS

8 PROTEOMICS MARKET, BY SERVICE

8.1 INTRODUCTION
8.2 CORE PROTEOMICS SERVICES
- 8.2.1 PROTEIN IDENTIFICATION SERVICES
  - 8.2.1.1 Rising need for protein identification and molecular weight analysis to boost market growth
- 8.2.2 QUANTITATIVE PROTEOMICS SERVICES
  - 8.2.2.1 Rapid and low-cost alternatives to help understand global protein expression and modifications
- 8.2.3 PROTEIN CHARACTERIZATION SERVICES
  - 8.2.3.1 Characterization studies to help study complex protein structure, drug development, and PTMs
- 8.2.4 PROTEIN PURIFICATION SERVICES
  - 8.2.4.1 Protein purification to maximize yield and purity of protein of interest
- 8.2.5 PROTEIN SEPARATION SERVICES
  - 8.2.5.1 Technological advancements and use in downstream applications to augment segment growth
- 8.2.6 PROTEIN SEQUENCING SERVICES
  - 8.2.6.1 Identification and characterization of PTMs to favor protein sequencing and research
- 8.2.7 CUSTOM ASSAY SERVICES
  - 8.2.7.1 Custom assays to improve validation or consistency of protein analysis procedures
8.3 BIOINFORMATICS SERVICES
- 8.3.1 LESSER ANALYSIS TIME AND FAVORABLE GOVERNMENT INITIATIVES TO SPUR MARKET GROWTH

9 PROTEOMICS MARKET, BY SOFTWARE

9.1 INTRODUCTION
- 9.1.1 BIOINFORMATICS TOOLS
  - 9.1.1.1 Need for data management and advancements in bioinformatics to augment market growth
- 9.1.2 BIOINFORMATICS DATABASES
  - 9.1.2.1 Need to store proteomics data and integrate other omics databases to drive market

10 PROTEOMICS MARKET, BY APPLICATION

10.1 INTRODUCTION
10.2 CLINICAL DIAGNOSTICS
- 10.2.1 CANCER
  - 10.2.1.1 Rising prevalence of cancer to propel market growth
- 10.2.2 INFECTIOUS DISEASES
  - 10.2.2.1 Technological advancements and need for effective disease diagnosis to support market growth
- 10.2.3 DIABETES
  - 10.2.3.1 Need for advanced diagnostic technologies and high diabetes prevalence to aid market growth
- 10.2.4 NEUROLOGICAL DISORDERS
  - 10.2.4.1 Growing target patient population and increasing research grants to fuel market growth
- 10.2.5 AUTOIMMUNE DISEASES
  - 10.2.5.1 Increasing patient population and growing focus on immunology-based research to propel market growth
- 10.2.6 CARDIOVASCULAR DISEASES
  - 10.2.6.1 High burden of cardiovascular diseases to spur adoption of reliable diagnostic tools
- 10.2.7 OTHER CLINICAL DIAGNOSTIC APPLICATIONS
10.3 DRUG DISCOVERY & DEVELOPMENT
- 10.3.1 TARGET DISCOVERY
  - 10.3.1.1 Increased demand for personalized medicine to support segment growth
- 10.3.2 LEAD IDENTIFICATION
  - 10.3.2.1 Lead identification to be essential in drug discovery and characterization
- 10.3.3 LEAD OPTIMIZATION
  - 10.3.3.1 Need for optimizing drug efficacy and safety to spur segment growth
- 10.3.4 PRECLINICAL STUDIES
  - 10.3.4.1 Integration of proteomics in preclinical studies to refine drug safety and efficacy
10.4 OTHER APPLICATIONS

11 PROTEOMICS MARKET, BY END USER

11.1 INTRODUCTION
11.2 BIOPHARMACEUTICAL COMPANIES
- 11.2.1 LOW OPERATING COSTS AND RAPID DRUG ANALYSIS TO DRIVE MARKET
11.3 ACADEMIC AND RESEARCH INSTITUTES
- 11.3.1 INCREASING RESEARCH FUNDING FOR PRECISION MEDICINE TO BOOST MARKET GROWTH
11.4 HOSPITALS
- 11.4.1 GROWING PREVALENCE OF IMMUNODEFICIENCY DISEASES AND SERUM PROTEIN DISORDERS TO BOOST MARKET GROWTH
11.5 CLINICAL LABORATORIES
- 11.5.1 INCREASING OUTSOURCING OF DIAGNOSTIC TESTS TO SUPPORT MARKET GROWTH
11.6 OTHER END USERS

12 PROTEOMICS MARKET, BY REGION

12.1 INTRODUCTION
12.2 NORTH AMERICA
- 12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
- 12.2.2 US
  - 12.2.2.1 US to dominate North American proteomics market during study period
- 12.2.3 CANADA
  - 12.2.3.1 Favorable government initiatives and high incidence of cancer to support market growth
12.3 EUROPE
- 12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
- 12.3.2 GERMANY
  - 12.3.2.1 Well-established pharmaceutical industry and increased government funding to augment market growth
- 12.3.3 UK
  - 12.3.3.1 Developed life science industry and increased academia-industry partnerships to augment market growth
- 12.3.4 FRANCE
  - 12.3.4.1 High investments in life science R&D and increased demand for personalized therapeutics to aid market growth
- 12.3.5 SWITZERLAND
  - 12.3.5.1 Well-established pharmaceutical and biotechnology industry and increased investments in life science R&D to drive market
- 12.3.6 ITALY
  - 12.3.6.1 High private and public R&D funding and favorable government initiatives to favor market growth
- 12.3.7 SPAIN
  - 12.3.7.1 Well-established network of research centers, universities, and hospitals to aid market growth
- 12.3.8 REST OF EUROPE
12.4 ASIA PACIFIC
- 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
- 12.4.2 CHINA
  - 12.4.2.1 Rising government R&D investments and increasing focus on healthcare product manufacturing to fuel market growth
- 12.4.3 JAPAN
  - 12.4.3.1 Large geriatric population and strong pharmaceutical research base to drive market
- 12.4.4 INDIA
  - 12.4.4.1 Increasing focus on proteomics and genomic research to support market growth
- 12.4.5 SOUTH KOREA
  - 12.4.5.1 Developed medical tourism and advanced healthcare infrastructure to propel market growth
- 12.4.6 AUSTRALIA
  - 12.4.6.1 Favorable government initiatives and high R&D investments to favor market growth
- 12.4.7 REST OF ASIA PACIFIC
12.5 LATIN AMERICA
- 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
- 12.5.2 BRAZIL
  - 12.5.2.1 Increasing contract research and manufacturing activities to drive market
- 12.5.3 MEXICO
  - 12.5.3.1 Strong pharmaceutical industry and increased government support to augment market growth
- 12.5.4 REST OF LATIN AMERICA
12.6 MIDDLE EAST
- 12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
- 12.6.2 GCC COUNTRIES
  - 12.6.2.1 Saudi Arabia
    - 12.6.2.1.1 Increasing government healthcare investments and developing pharmaceuticals industry to boost market growth
  - 12.6.2.2 UAE
    - 12.6.2.2.1 High R&D expenditure and developed health infrastructure to drive market
  - 12.6.2.3 Rest of GCC Countries
- 12.6.3 REST OF MIDDLE EAST
12.7 AFRICA
- 12.7.1 FAVORABLE GOVERNMENT INITIATIVES AND ADVANCEMENTS IN PERSONALIZED MEDICINES TO PROPEL MARKET GROWTH
- 12.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

13 COMPETITIVE LANDSCAPE

13.1 INTRODUCTION
13.2 KEY PLAYER STRATEGY/RIGHT TO WIN
- 13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PROTEOMICS MARKET
13.3 REVENUE ANALYSIS, 2021-2023
13.4 MARKET SHARE ANALYSIS, 2023
13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
- 13.5.1 STARS
- 13.5.2 EMERGING LEADERS
- 13.5.3 PERVASIVE PLAYERS
- 13.5.4 PARTICIPANTS
- 13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
  - 13.5.5.1 Company footprint
  - 13.5.5.2 Instrumentation technology footprint
  - 13.5.5.3 Reagent footprint
  - 13.5.5.4 Service footprint
  - 13.5.5.5 Software footprint
  - 13.5.5.6 Region footprint
13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
- 13.6.1 PROGRESSIVE COMPANIES
- 13.6.2 RESPONSIVE COMPANIES
- 13.6.3 DYNAMIC COMPANIES
- 13.6.4 STARTING BLOCKS
- 13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
13.7 COMPANY VALUATION AND FINANCIAL METRICS
13.8 BRAND/PRODUCT COMPARISON
13.9 COMPETITIVE SCENARIO
- 13.9.1 PRODUCT LAUNCHES
- 13.9.2 DEALS
- 13.9.3 EXPANSIONS

14 COMPANY PROFILES

14.1 KEY PLAYERS
- 14.1.1 THERMO FISHER SCIENTIFIC INC.
  - 14.1.1.1 Business overview
  - 14.1.1.2 Products/Services/Solutions offered
- 14.1.2 RECENT DEVELOPMENTS
  - 14.1.2.1 Product launches
  - 14.1.2.2 Deals
  - 14.1.2.3 MnM view
    - 14.1.2.3.1 Key strengths
    - 14.1.2.3.2 Strategic choices
    - 14.1.2.3.3 Weaknesses and competitive threats
- 14.1.3 AGILENT TECHNOLOGIES, INC.
  - 14.1.3.1 Business overview
  - 14.1.3.2 Products/Services/Solutions offered
  - 14.1.3.3 Recent developments
    - 14.1.3.3.1 Product launches
    - 14.1.3.3.2 Deals
  - 14.1.3.4 MnM view
    - 14.1.3.4.1 Key strengths
    - 14.1.3.4.2 Strategic choices
    - 14.1.3.4.3 Weaknesses and competitive threats
- 14.1.4 MERCK KGAA
  - 14.1.4.1 Business overview
  - 14.1.4.2 Products/Services/Solutions offered
  - 14.1.4.3 MnM view
    - 14.1.4.3.1 Key strengths
    - 14.1.4.3.2 Strategic choices
    - 14.1.4.3.3 Weaknesses and competitive threats
- 14.1.5 DANAHER CORPORATION
  - 14.1.5.1 Business overview
  - 14.1.5.2 Products/Services/Solutions offered
  - 14.1.5.3 Recent developments
    - 14.1.5.3.1 Product launches
    - 14.1.5.3.2 Deals
  - 14.1.5.4 MnM view
    - 14.1.5.4.1 Key strengths
    - 14.1.5.4.2 Strategic choices
    - 14.1.5.4.3 Weaknesses and competitive threats
- 14.1.6 SHIMADZU CORPORATION
  - 14.1.6.1 Business overview
  - 14.1.6.2 Products/Services/Solutions offered
  - 14.1.6.3 Recent developments
    - 14.1.6.3.1 Product launches
    - 14.1.6.3.2 Expansions
  - 14.1.6.4 MnM view
    - 14.1.6.4.1 Key strengths
    - 14.1.6.4.2 Strategic choices
    - 14.1.6.4.3 Weaknesses and competitive threats
- 14.1.7 WATERS CORPORATION
  - 14.1.7.1 Business overview
  - 14.1.7.2 Products/Services/Solutions offered
  - 14.1.7.3 Recent developments
    - 14.1.7.3.1 Product launches
    - 14.1.7.3.2 Deals
- 14.1.8 BIO-RAD LABORATORIES, INC.
  - 14.1.8.1 Business overview
  - 14.1.8.2 Products/Services/Solutions offered
  - 14.1.8.3 Recent developments
    - 14.1.8.3.1 Product launches
- 14.1.9 BRUKER
  - 14.1.9.1 Business overview
  - 14.1.9.2 Products/Services/Solutions offered
  - 14.1.9.3 Recent developments
    - 14.1.9.3.1 Product launches
    - 14.1.9.3.2 Deals
- 14.1.10 REVVITY
  - 14.1.10.1 Business overview
  - 14.1.10.2 Products/Services/Solutions offered
  - 14.1.10.3 Recent developments
    - 14.1.10.3.1 Deals
- 14.1.11 ILLUMINA, INC.
  - 14.1.11.1 Business overview
  - 14.1.11.2 Products/Services/Solutions offered
  - 14.1.11.3 Recent developments
    - 14.1.11.3.1 Deals
- 14.1.12 PROMEGA CORPORATION
  - 14.1.12.1 Business overview
  - 14.1.12.2 Products/Services/Solutions offered
- 14.1.13 EUROFINS SCIENTIFIC
  - 14.1.13.1 Business overview
  - 14.1.13.2 Products/Services/Solutions offered
  - 14.1.13.3 Recent developments
    - 14.1.13.3.1 Deals
- 14.1.14 QIAGEN
  - 14.1.14.1 Business overview
  - 14.1.14.2 Products/Services/Solutions offered
  - 14.1.14.3 Recent developments
    - 14.1.14.3.1 Product launches
    - 14.1.14.3.2 Deals
- 14.1.15 CHARLES RIVER LABORATORIES
  - 14.1.15.1 Business overview
  - 14.1.15.2 Products/Services/Solutions offered
  - 14.1.15.3 Recent developments
    - 14.1.15.3.1 Product launches
    - 14.1.15.3.2 Deals
- 14.1.16 PROTAGENE
  - 14.1.16.1 Business overview
  - 14.1.16.2 Products/Services/Solutions offered
14.2 OTHER PLAYERS
- 14.2.1 CREATIVE PROTEOMICS, US
- 14.2.2 HORIBA JAPAN LTD.
- 14.2.3 SENGENICS CORPORATION LLC
- 14.2.4 LABVANTAGE-BIOMAX GMBH
- 14.2.5 FIOS GENOMICS
- 14.2.6 AZENTA US, INC.
- 14.2.7 MEDGENOME
- 14.2.8 BIOGNOSYS AG
- 14.2.9 MACROGEN, INC.
- 14.2.10 CELL SIGNALING TECHNOLOGY, INC.

15 APPENDIX

15.1 DISCUSSION GUIDE
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
15.3 CUSTOMIZATION OPTIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS